IL-10 restores MHC class I expression and interferes tumor immunity in papillary thyroid cancer with concomitant Hashimotos thyroiditis*Corresponding Author: Tian Liao, Department of Head and Neck Surgery, Fudan University, Shanghai,200032, China, Tel: +86-021-64175590, Fax: 0086-021-64175590, Email: [email protected]
Received Date: Jul 18, 2019 / Accepted Date: Aug 01, 2019 / Published Date: Aug 12, 2019
Citation: Lu ZW, Hua JQ, Han LT, Zhang TT, Wei WJ, et al. (2019) IL-10 Restores MHC Class I Expression and Interferes Tumor Immunity in Papillary Thyroid Cancer with Concomitant Hashimoto’s Thyroiditis. Diagn Pathol Open 4: 152.
Copyright: © 2019 Lu ZW, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Purpose: The incidence of papillary thyroid cancer (PTC) with concomitant Hashimoto’s thyroiditis (HT) is increasing. Interleukin-10 (IL-10) is a cytokine previously reported to be elevated in this condition. Evidence from multiple human malignancies showed IL-10 participated in tumor immunity and exhibited therapeutic potential. The aim of this study is to investigate whether IL-10 interferes tumor immunity in PTC with concomitant HT.
Method: Expression of IL-10 and major histocompatibility complex (MHC) class I were compared on PTC tissues with or without concomitant HT. PTC cell lines K1 and TPC-1 were stimulated with IL-10 and analyzed for MHC class I expression afterwards. T cell activation, production of Interleukin-2 (IL-2) and IFN-γ and programmed death-1 (PD-1) expression were assessed by coculture of donor peripheral blood lymphocytes (PBLs) with IL-10 pretreated PTC cells. Programmed death-ligand 1 (PD-L1) expression was measured in PTC tissues and IL-10 pretreated cells of K1 and TPC-1.
Results: Increased level of IL-10 and MHC class I were observed in PTC with concomitant HT. IL-10 stimulation increased MHC class I expression of PTC cells in vitro. Coculture of PBLs with IL-10 pretreated PTC cells enhanced T cell activation (%CD25+ of CD3+T cells) and increased IL-2 production along with decreased IFN-γ secretion and PD-1 expression. Reduced PD-L1 expression was seen in PTC+HT tissue samples and IL-10 stimulated PTC cell lines.
Conclusion: Elevated IL-10 expression in PTC with concomitant HT restores MHC class I expression and interferes tumor immunity. IL-10 may facility cancer immunotherapy in MHC class I reduced malignancies.